Literature DB >> 1327512

Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form.

H Takiuchi1, T Tada, X F Li, M Ogata, T Ikeda, S Fujimoto, H Fujiwara, T Hamaoka.   

Abstract

We investigated the capacities of various tumor types to generate an active versus latent form of transforming growth factor beta (TGF-beta) in its culture supernatants (SNs). Tumor cell lines were divided into three types depending on the form and magnitude of TGF-beta detected in their culture SNs: some (2 of 7 lines) generated mostly an active form (Type A); others (4 of 7) generated exclusively a latent form (Type B); and the remaining line (1 of 7) produced only marginal levels of active/latent TGF-beta (Type C). When Type A tumor cells were cultured at lower numbers, cultures failed to generate active TGF-beta. However, the addition of Type B tumor cell culture SNs containing only a latent form of TGF-beta resulted in the generation of the potent activity of active TGF-beta. This capacity was observed for another Type A tumor but not for other types (Type B and Type C). An active form of TGF-beta was detected in culture SNs of Type A tumor cells as early as 3-6 h after the addition of Type B tumor culture SNs. The emergence of an active form of TGF-beta was also observed in cultures of Type A tumor cells, the protein synthesis of which was almost completely inhibited by pretreatment with cycloheximide. Moreover, the Type B tumor SN used for the induction of active TGF-beta activity was found to contain latent TGF-beta with an apparent molecular weight of about 200,000. Type A tumor cells were also capable of generating active TGF-beta by the addition of recombinant TGF-beta of latent form with a small molecular weight (about 60,000), although the generation of active TGF-beta was much weaker after the addition of small latent TGF-beta than after the addition of large latent TGF-beta. Taken collectively, these results indicate that particular types of tumor cells have the capacity to generate an active form of TGF-beta and that such capacity can be attributed to their potential to convert TGF-beta from a latent (mainly large type) to an active form.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327512

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Interactions between interferon gamma and retinoic acid with transforming growth factor beta in the induction of immune recognition molecules.

Authors:  R Darley; A Morris; J Passas; W Bateman
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

2.  Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.

Authors:  S R Sue; R S Chari; F M Kong; J J Mills; R L Fine; R L Jirtle; W C Meyers
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

3.  MED15, transforming growth factor beta 1 (TGF-β1), FcγRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma.

Authors:  Maryam Elahi; Vahid Rakhshan
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

4.  Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line.

Authors:  M Horimoto; J Kato; R Takimoto; T Terui; Y Mogi; Y Niitsu
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

5.  Dysregulation of autocrine TGF-beta isoform production and ligand responses in human tumour-derived and Ha-ras-transfected keratinocytes and fibroblasts.

Authors:  M S Fahey; I C Paterson; A Stone; A J Collier; Y L Heung; M Davies; V Patel; E K Parkinson; S S Prime
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

6.  Rat testicular germ cells and Sertoli cells release different types of bioactive transforming growth factor beta in vitro.

Authors:  Bart L Haagmans; Jos W Hoogerbrugge; Axel P N Themmen; Katja J Teerds
Journal:  Reprod Biol Endocrinol       Date:  2003-02-05       Impact factor: 5.211

7.  Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta.

Authors:  H Naganuma; A Sasaki; E Satoh; M Nagasaka; S Nakano; S Isoe; K Tasaka; H Nukui
Journal:  Jpn J Cancer Res       Date:  1994-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.